One of the Nigeria's healthcare manufacturing companies, Sygen Pharmaceuticals, has promised to improve lives of citizens through innovative sciences, especially in the communities where they operate, reports ITREALMS.
Speaking at the formal brand launch, held in Onikan, Lagos, the Chief Executive Officer, Sygen, Charles Ogunwuyi, said Sygen manufactures and markets a wide range of products including anti-malaria, anti-hypertensive and antidiabetics, drugs among other products.
He explained that Sygen aims to spotlight its plans to transform the pharmaceutical sector in Nigeria and value chain in the West African region through research and innovation.
Ogunwuyi, noted that Sygen Pharmaceutical formally introduces corporate brand in Nigeria, with the goal of promoting communal well-being for all Nigerians. Established in March 2019, with the plans to drive innovation in the pharmaceutical industry including promoting overall communal well-being for all Nigerians.
He said the pharmaceutical company is led by a management team with extensive multinational and international work experience, and determined to develop and create access to high-quality medicines that yield successful outcomes and improve patients’ quality of life in the communities where it operates.
The General Manager (GM) Sales for Lagos and Southwest, Kachi Akwari said, the innovative pharmaceutical company subsequently acquired the assets of Nigerian German Chemicals (NGC) Plc, to expand its pharmaceutical product portfolio.
He said, Sygen Pharmaceutical’s product portfolio currently includes drugs in the following categories:, antidiabetics, antipyretics, multivitamin, analgesic, antirheumatic, antifungal, antispasmodic, among others.
“Sygen Pharmaceutical was established to grant access to high-quality medicines that yield successful outcomes and improve the quality of life of patients in our community; through our innovative approach to enhancing healthcare outcomes. At Sygen, we look beyond the functionality of providing medicines and seek to drive the total well-being of communities in a way that is vital to society” Akwari said.
Also, he said there is a need in the pharmaceutical industry to shift the focus from humans as patients to people living in thriving communities. As Sygen Pharmaceutical puts this in practice with the goal of promoting communal well-being and thriving communities.
Akwari noted that Sygen Pharmaceutical is building a reputation with its product quality and supply continuity. The Company continues to build a wide-ranging portfolio of products across brands and plans to rapidly expand its product line.
“With its formal brand launch, Sygen pharmaceutical will redirect the focus on medicine as a function of ill health to providing a better life for communities altogether” he said, pointing out that since inception, Sygen Pharma, has established itself as a reputable organisation within the pharmaceutical and healthcare industry and has gained the trust and respect of key stakeholders.
“In addition to the portfolio of branded products acquired from NGC,Sygen will continue to grow its product portfolio across various therapeutic areas. The organisation is driven by the quest to make a difference in the lives of people and communities. As a result, Sygen Pharma strives for continuous improvement and innovation geared toward expanding access to good-quality medicines in communities”.
Akwari further said that Sygen Pharmaceutical acquired NGC because is a company that had operated in Nigeria for almost 60 years and has a range of legacy brands with strong residual equity in its product portfolio.
Sygen Pharmaceuticals Limited is an ISO 9001:2015 Certified Company by Société Générale de Surveillance (SGS), and benchmarks its materials and products specification with the Nigeria statutory, Legal and Regulatory Guidelines/Regulations, United States Pharmacopeia (USP) and British Pharmacopeia (BP) standards.
*Paul Adunwoke
He explained that Sygen aims to spotlight its plans to transform the pharmaceutical sector in Nigeria and value chain in the West African region through research and innovation.
Ogunwuyi, noted that Sygen Pharmaceutical formally introduces corporate brand in Nigeria, with the goal of promoting communal well-being for all Nigerians. Established in March 2019, with the plans to drive innovation in the pharmaceutical industry including promoting overall communal well-being for all Nigerians.
He said the pharmaceutical company is led by a management team with extensive multinational and international work experience, and determined to develop and create access to high-quality medicines that yield successful outcomes and improve patients’ quality of life in the communities where it operates.
The General Manager (GM) Sales for Lagos and Southwest, Kachi Akwari said, the innovative pharmaceutical company subsequently acquired the assets of Nigerian German Chemicals (NGC) Plc, to expand its pharmaceutical product portfolio.
He said, Sygen Pharmaceutical’s product portfolio currently includes drugs in the following categories:, antidiabetics, antipyretics, multivitamin, analgesic, antirheumatic, antifungal, antispasmodic, among others.
“Sygen Pharmaceutical was established to grant access to high-quality medicines that yield successful outcomes and improve the quality of life of patients in our community; through our innovative approach to enhancing healthcare outcomes. At Sygen, we look beyond the functionality of providing medicines and seek to drive the total well-being of communities in a way that is vital to society” Akwari said.
Also, he said there is a need in the pharmaceutical industry to shift the focus from humans as patients to people living in thriving communities. As Sygen Pharmaceutical puts this in practice with the goal of promoting communal well-being and thriving communities.
Akwari noted that Sygen Pharmaceutical is building a reputation with its product quality and supply continuity. The Company continues to build a wide-ranging portfolio of products across brands and plans to rapidly expand its product line.
“With its formal brand launch, Sygen pharmaceutical will redirect the focus on medicine as a function of ill health to providing a better life for communities altogether” he said, pointing out that since inception, Sygen Pharma, has established itself as a reputable organisation within the pharmaceutical and healthcare industry and has gained the trust and respect of key stakeholders.
“In addition to the portfolio of branded products acquired from NGC,Sygen will continue to grow its product portfolio across various therapeutic areas. The organisation is driven by the quest to make a difference in the lives of people and communities. As a result, Sygen Pharma strives for continuous improvement and innovation geared toward expanding access to good-quality medicines in communities”.
Akwari further said that Sygen Pharmaceutical acquired NGC because is a company that had operated in Nigeria for almost 60 years and has a range of legacy brands with strong residual equity in its product portfolio.
Sygen Pharmaceuticals Limited is an ISO 9001:2015 Certified Company by Société Générale de Surveillance (SGS), and benchmarks its materials and products specification with the Nigeria statutory, Legal and Regulatory Guidelines/Regulations, United States Pharmacopeia (USP) and British Pharmacopeia (BP) standards.
*Paul Adunwoke
No comments:
Post a Comment